Korea Exchange · Healthcare
Samjin Pharmaceuticals stock from India: price, numbers and tax
Samjin Pharmaceuticals (005500) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Samjin Pharmaceuticals at a glance
- Price
- ₩20,100.00+₩280.00 (1.41%)
- Market cap
- ₩254.42B
- Day range
- ₩19,710.00 – ₩20,300.00
- P/E
- 10.75
- Dividend yield
- 3.98%
- Volume
- 45.50K
- 1 month
- +7.66%
- 6 months
- +11.85%
- YTD
- +1.77%
- 1 year
- +3.93%
- 5 years
- -18.79%
Samjin Pharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩309.1B | ₩308.3B | ₩292.1B | ₩274.0B | ₩250.1B |
| Gross profit | ₩153.0B | ₩129.0B | ₩145.9B | ₩117.7B | ₩117.8B |
| Operating income | ₩24.7B | ₩31.6B | ₩19.5B | ₩23.2B | ₩33.9B |
| Net income | ₩24.2B | ₩39.2B | ₩18.9B | ₩21.9B | ₩28.4B |
| Earnings per share | ₩1,962.68 | ₩3,110.66 | ₩1,460.00 | ₩1,727.82 | ₩2,308.75 |
| EBITDA | ₩44.5B | ₩65.9B | ₩36.6B | ₩36.8B | ₩42.4B |
| Total assets | ₩470.5B | ₩425.2B | ₩419.9B | ₩406.6B | ₩332.5B |
| Total debt | ₩135.9B | ₩121.4B | ₩118.6B | ₩87.5B | ₩54.5B |
| Cash and short-term investments | ₩12.9B | ₩3.7B | ₩4.0B | ₩4.7B | ₩11.7B |
| Shareholders' equity | ₩290.4B | ₩261.7B | ₩265.4B | ₩275.3B | ₩234.2B |
| Operating cash flow | ₩22.2B | ₩38.2B | ₩8.3B | ₩17.3B | ₩24.0B |
| Free cash flow | ₩10.0B | ₩19.8B | −₩12.4B | −₩18.2B | −₩50.6B |
| Capital expenditure | −₩12.3B | −₩18.3B | −₩20.7B | −₩35.5B | −₩74.6B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Kwang Dong Pharmaceutical | 009290.KS | ₩6,920.00 | ₩343.65B |
| JW | 096760.KS | ₩4,105.00 | ₩284.03B |
| AptaBio Therapeutics | 293780.KQ | ₩7,940.00 | ₩223.06B |
| REYON Pharmaceutical | 102460.KS | ₩10,280.00 | ₩188.55B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| Chong Kun Dang | 001630.KS | ₩37,250.00 | ₩177.33B |
| Daewon Pharmaceutical | 003220.KS | ₩8,190.00 | ₩175.54B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Samjin Pharmaceuticals from India
What Samjin Pharmaceuticals does
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. Samjin Pharmaceuticals operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Samjin Pharmaceuticals shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.